Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools GIST

GIST

Programs, trials, and reported response and survival for gastrointestinal stromal tumor.

Data as of 11.07.2026

All drugs

Sunitinib

Sutent

Stage Approved

Sponsor Pfizer

Route oral capsule

Modality small molecule

Class multi-kinase TKI (type II)

Mechanism kinase inhibitor; label boxed warning for hepatotoxicity

Target KIT (TEC-0117)

Target PDGFRA

Target VEGFR

Sources

fda, as of 2026-11-07

https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=43a4d7f8-48ae-4a63-9108-2fa8e3ea9d9c

Time-to-tumor progression [median, weeks (95% CI)] 27.3 (16.0, 32.1) 6.4 (4.4, 10.0) ... Progression-free survival [median, weeks] 24.1 (11.1, 28.3) 6.0 (4.4, 9.9) ... Objective response rate (PR) 6.8 ... 0

Sutent USPI boxed warning (hepatotoxicity) and section 14.1, Table 10, Study 1 (NCT00075218)

registry, as of 2026-11-07

https://clinicaltrials.gov/study/NCT00075218

A Phase III, Randomized, Double-Blind, Placebo-Controlled Study Of SU011248 In The Treatment Of Patients With Imatinib Mesylate (Gleevec Tm, Glivec)-Resistant Or Intolerant Malignant Gastrointestinal Stromal Tumor

ClinicalTrials.gov API v2 record, retrieved 2026-11-07

Studies

Study 1

Registry NCT00075218

Phase Phase 3

Status Completed

Enrollment 361

Start 2003-12

Primary completion 2008-05

Study completion 2008-05

Sunitinib 50 mg, 4 weeks on 2 off

Dose 50 mg

Regimen once daily, Schedule 4/2

Comparator placebo

Population GIST after imatinib progression or intolerance

Estimand ITT

median time to tumor progression: 27.3 weeks, interim analysis

median progression-free survival: 24.1 weeks, interim analysis

objective response rate (partial responses): 6.8%, interim analysis

Placebo

Dose placebo

Regimen once daily

Population GIST after imatinib progression or intolerance

Estimand ITT

median time to tumor progression: 6.4 weeks, interim analysis

median progression-free survival: 6 weeks, interim analysis